Observational studyJCO oncology practice2024

Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor-Based Regimens in the Second-Line Setting.

Bita Fakhri et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.